Liver transplant recipient with concomitant cutaneous and visceral leishmaniasis

Özcan, Deren; Seckın, Denız; Allahverdiyev, Adil M.; Weina, Peter J.; Aydın, Hakan; Özçay, Figen; Haberal, Mehmet

doi:10.1111/j.1399-3046.2006.00660.x

Cited by 24 publications

(42 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two cases of PKDL have been reported, in both of which cutaneous symptoms developed four years after the treatment of visceral leishmaniasis 11,17 . In addition, two patients with concurrent cutaneous and visceral leishmaniasis have been reported, one of whom died despite treatment with multi‐drug therapy 18,19 …”

Section: Discussionmentioning

confidence: 99%

Dissemination of localized cutaneous leishmaniasis in an organ transplant recipient: case report and literature review

Zandieh

Dastgheib

2012

Int J Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Dissemination of localized cutaneous leishmaniasis in an organ transplant recipient: case report and literature review

Zandieh

Dastgheib

2012

Int J Dermatology

View full text Add to dashboard Cite

“…Bone marrow or solid organ transplantation [89][90][91][92][93][94][95] and therapy with immunosuppressive or biologic drugs [96][97][98] also have been associated with the appearance of ATL. In immunosuppressed patients, CL is characterized by atypical cutaneous lesions and persistent negativity of diagnostic tests 91 .…”

Section: Resultsmentioning

confidence: 99%

Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence

Silva

Galvão

Gomes

et al. 2013

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Revista da Sociedade Brasileira de Medicina Tropical 46(6):669-677, Nov-Dec, 2013http://dx.doi. org/10.1590/0037-8682-0104-2013 Address to: Dr a Juliana Saboia Fontenele e Silva. Lab. ABSTRACT We aimed to assess and synthesize the information available in the literature regarding the treatment of American tegumentary leishmaniasis in special populations. We searched MEDLINE (via PubMed), EMBASE, LILACS, SciELO, Scopus, Cochrane Library and mRCT databases to identify clinical trials and observational studies that assessed the pharmacological treatment of the following groups of patients: pregnant women, nursing mothers, children, the elderly, individuals with chronic diseases and individuals with suppressed immune systems. The quality of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. The available evidence suggests that the treatments of choice for each population or disease entity are as follows: nursing mothers and children (meglumine antimoniate or pentamidine), patients with renal disease (amphotericin B or miltefosine), patients with heart disease (amphotericin B, miltefosine or pentamidine), immunosuppressed patients (liposomal amphotericin), the elderly (meglumine antimoniate), pregnant women (amphotericin B) and patients with liver disease (no evidence available). The quality of evidence is low or very low for all groups. Accurate controlled studies are required to fi ll in the gaps in evidence for treatment in special populations. Post-marketing surveillance programs could also collect relevant information to guide treatment decision-making.

show abstract

“…1,8 Although information on other protozoan infections is available, there are no reports where Leishmania infections were investigated in stem cell transplantations. In this study, the interaction between different types of Leishmania parasites and ADMSCs has been investigated in vitro .…”

Section: Discussionmentioning

confidence: 99%

“…It is simply because of the fact that reactivation of Leishmania parasites after immunosuppressive treatment in organ transplantations has been reported in several studies. 1,8 Although several screening methodologies can be performed to detect Leishmania parasites in stem cell transplantations, one of the most important problems is the diagnosis of the leishmaniasis disease. For the diseases that cause latent infections such as Leishmania , the diagnosis become very difficult.…”

Section: Discussionmentioning

confidence: 99%

“…7 In one of our previous studies, it was shown that Leishmania infection could be transmitted during pediatric organ transplantations. 8 However, there is no report that has been published on the existence of Leishmania parasites in stem cell transplantations. Distinct from other infections, the lack of clinical evidence related to Leishmania infections in stem cell transplantations could be because of the facts that leishmaniasis is difficult to diagnose and that it sometimes leads to a misdiagnosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adipose Tissue-Derived Mesenchymal Stem Cells as a New Host Cell in Latent Leishmaniasis

Allahverdiyev¹,

Bağırova²,

Elcicek³

et al. 2011

The American Society of Tropical Medicine and Hygiene

Self Cite

View full text Add to dashboard Cite

Some protozoan infections such as Toxoplasma, Cryptosporidium, and Plasmodium can be transmitted through stem cell transplantations. To our knowledge, so far, there is no study about transmission of Leishmania parasites in stem cell transplantation and interactions between parasites and stem cells in vitro. Therefore, the aim of this study was to investigate the interaction between different species of Leishmania parasites and adipose tissue-derived mesenchymal stem cells (ADMSCs). ADMSCs have been isolated, cultured, characterized, and infected with different species of Leishmania parasites (L. donovani, L. major, L. tropica, and L. infantum). Infectivity was examined by Giemsa staining, microculture, and polymerase chain reaction methods. As a result, infectivity of ADMSCs by Leishmania parasites has been determined for the first time in this study. According to our findings, it is very important that donors are screened for Leishmania parasites before stem cell transplantations in regions where leishmaniasis is endemic.

show abstract

Liver transplant recipient with concomitant cutaneous and visceral leishmaniasis

Cited by 24 publications

References 18 publications

Dissemination of localized cutaneous leishmaniasis in an organ transplant recipient: case report and literature review

Dissemination of localized cutaneous leishmaniasis in an organ transplant recipient: case report and literature review

Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence

Adipose Tissue-Derived Mesenchymal Stem Cells as a New Host Cell in Latent Leishmaniasis

Contact Info

Product

Resources

About